Trials / Completed
CompletedNCT01736514
A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout
A Randomized, Open Label, Multicenter, Allopurinol- Controlled Study to Assess the Safety and Efficacy of Oral Febuxostat in Patients With Gout
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- Astellas Pharma Taiwan, Inc. · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open label, randomized, allopurinol-controlled, parallel-design study. Approximately 120 subjects will be randomly assigned in 1:1 ratio to receive febuxostat, or allopurinol for subjects with gout.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | febuxostat | oral |
| DRUG | Allopurinol | oral |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2012-11-29
- Last updated
- 2014-10-29
Locations
4 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01736514. Inclusion in this directory is not an endorsement.